Saskia Middeldorp MD

Saskia Middeldorp is Professor of Medicine and Head of the Department of Internal Medicine of the Radboud University Medical Center in Nijmegen, The Netherlands. Prior to her transfer to Nijmegen in January 2021, she has been a professor of Medicine at Amsterdam University Medical Centers for over 10 years, leading the clinical thrombosis and haemostasis research lines of the Department of Vascular Medicine.

Her present research focuses on several aspects of hereditary and acquired thrombophilia, women’s issues in thrombosis and haemostasis, and the clinical evaluation of new anticoagulants. She is principal investigator of practice-changing trials such as the investigator-initiated ALIFE, ALIFE2 and Highlow randomized controlled trials.

Saskia Middeldorp is elected council member of the International Society of Thrombosis and Haemostasis, immediate past chair of the INVENT-VTE network, Associate Editor of the Journal of Thrombosis and Haemostasis and Editorial Board Member of Blood.

In December 2016, she held the Ham-Wasserman Lecture and received the accompanying award in recognition of pioneering work in inherited thrombophilia at the annual American Society of Hematology (ASH) meeting in San Diego. In October 2021, she received the Heijmans van den Bergh penning, a once-per-five year honorary distinction of the Netherlands Internal Medicine Society for her achievements in terms of science, education, governance and being a role model for young internists.

She is member of the Venous Thrombosis Guideline Coordination Panel and chair of the Thrombophilia Chapter of ASH. Saskia Middeldorp has co-authored the Pregnancy chapter of the ASH pregnancy guideline in 2018 as well as the 9th Edition Antithrombotic Guidelines of the American College of Chest Physicians (ACCP) in 2012.

Saskia currently supervises 10 PhD students and has co-authored over 470 peer-reviewed papers and several book chapters, and reviews manuscripts for international scientific journals.